Literature DB >> 21039737

Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta.

Y Qiu1, Y Liu, Z Qi, W Wang, Z Kou, Q Zhang, G Liu, T Liu, Y Yang, X Yang, Y Xin, C Li, B Cui, S Huang, H Liu, L Zeng, Z Wang, R Yang, H Wang, X Wang.   

Abstract

The subunit vaccine SV1 (20 μg F1+10 μg rV270) has been identified as the optimal formulation in mice, which provided a good protection against plague in mice, guinea pigs and rabbits. To compare SV1 and SV2 (200 μg F1+100 μg rV270) with live attenuated vaccine EV76, antibody responses, protective efficacy, cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-10 and IL-12) production, CD4/CD8 ratio and CD69(+) T-cell activation marker were determined in sera of the immunized Chinese-origin rhesus macaques, Macaca mulatta. The immunized animals with SV1 or SV2 developed higher anti-rV270 IgG titre, while those immunized with EV76 elicited a negligible IgG to V antigen, indicating that subunit vaccine (SV) had an advantage over EV76 in terms of the indispensable role of anti-V antibody against Yersinia pestis. There was no significant antibody titre difference between SV1 and SV2, suggesting that the immune response may have been saturated at the dose level of SV1. There were no statistical changes for CD4/CD8 ratios, IL-4 and CD69 levels between the three-vaccine immunized groups. However, a significant higher level of IL-12 was observed in the EV76 immunized animals, indicating that EV76 had an advantage over SV in respect of cellular immunity. Complete protection was observed for the immunized animals with SV and EV76, revealing that SV has a similar protective efficacy with EV76 against 6×10⁶ CFU of Y. pestis challenge by subcutaneous route in Chinese-origin rhesus macaques.
© 2010 Beijing Institute of Microbiology and Epidemiology. Scandinavian Journal of Immunology © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039737     DOI: 10.1111/j.1365-3083.2010.02456.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  13 in total

1.  One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.

Authors:  Jialei Hu; Lei Jiao; Yuemei Hu; Kai Chu; Jingxin Li; Fengcai Zhu; Taishun Li; Zhiyuan Wu; Dong Wei; Fanyue Meng; Bingxiang Wang
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

2.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

3.  Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Authors:  Tatiana E Erova; Jason A Rosenzweig; Jian Sha; Giovanni Suarez; Johanna C Sierra; Michelle L Kirtley; Christina J van Lier; Maxim V Telepnev; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

4.  Acquisition of maternal antibodies both from the placenta and by lactation protects mouse offspring from Yersinia pestis challenge.

Authors:  Zhizhen Qi; Haihong Zhao; Qingwen Zhang; Yujing Bi; Lingling Ren; Xuecan Zhang; Hanqing Yang; Xiaoyan Yang; Qiong Wang; Cunxiang Li; Jiyuan Zhou; Youquan Xin; Yonghai Yang; Huiying Yang; Zongmin Du; Yafang Tan; Yanping Han; Yajun Song; Lei Zhou; Pingping Zhang; Yujun Cui; Yanfeng Yan; Dongsheng Zhou; Ruifu Yang; Xiaoyi Wang
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

Review 5.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 6.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 7.  Rational considerations about development of live attenuated Yersinia pestis vaccines.

Authors:  Wei Sun; Roy Curtiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

Review 8.  Plague vaccines: current developments and future perspectives.

Authors:  Valentina A Feodorova; Vladimir L Motin
Journal:  Emerg Microbes Infect       Date:  2012-11-07       Impact factor: 7.163

9.  The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

Authors:  E D Williamson
Journal:  Adv Prev Med       Date:  2011-09-29

10.  Histopathological observation of immunized rhesus macaques with plague vaccines after subcutaneous infection of Yersinia pestis.

Authors:  Guang Tian; Yefeng Qiu; Zhizhen Qi; Xiaohong Wu; Qingwen Zhang; Yujing Bi; Yonghai Yang; Yuchuan Li; Xiaoyan Yang; Youquan Xin; Cunxiang Li; Baizhong Cui; Zuyun Wang; Hu Wang; Ruifu Yang; Xiaoyi Wang
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.